| Name |
Format |
Description |
Link |
|
21 |
Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain
This study thus aimed to characterize the occurrence of genetic reassortment between the MP-12 strain and bunyavirus species closely related to RVFV. The Arumowot virus (AMTV) and Gouleako goukovirus (GOLV), are transmitted by mosquitoes in Africa. The results of this study showed that GOLV does not form detectable reassortant strains with the MP-12 strain in co-infected C6/36 cells. The AMTV also did not form any reassortant strains with MP-12 strain in co-infected C6/36 cells, due to the incompatibility among N, L, and Gn/Gc proteins. A lack of reassortant formation could be due to a functional incompatibility of N and L proteins derived from heterologous species, and due to a lack of packaging via heterologous Gn/Gc proteins. The MP-12 strain did, however, randomly exchange L-, M-, and S-segments with a genetic variant strain, rMP12-GM50, in culture cells. The MP-12 strain is thus unlikely to form any reassortant strains with AMTV or GOLV in nature. The supporting data for these observations are as follows: |
https://data.usaid.gov/d/tsnq-b69w |
|
21 |
Subcutaneous needle vaccination against Rift Valley fever virus (RVFV): Antibody response for goats, sheep and calves vaccinated with MP12 and MP12Nsm del vaccines analysed by PRNT 80% and commercial cELISAkit. cELISA results are expressed in inhibition percent (S/N%) and PRNT results in reciprocal of PRNT 80% neutralization titers. The overall purpose of the Feed the Future Innovation Lab for Rift Valley Fever Control in Agriculture is to increase the food supply by developing and applying a vaccine for the prevention of Rift Valley fever disease among livestock in Africa. Rift Valley Fever (RVF) is a mosquito-borne viral disease that continues to have a devastating impact on human and animal health in Africa. Since the discovery of RVF as the cause of an outbreak among sheep and humans during the early 1930s in the Rift Valley in Kenya, the disease has emerged as one of the most important zoonoses in Africa. The disease has and continues to affect the health of thousands to millions of humans and animals, and the livestock industry has lost millions of dollars, and therefore, affecting hundreds of millions of those whose livelihood depends on livestock, exaggerating poverty on already deprived communities.
Full dataset available in the file: Livestock_vaccinated_with_MP-12_MP-12_NSm-del_SubQ_Salekwa.xlsx |
https://data.usaid.gov/d/uhag-rm92 |
|
21 |
Vaccination of domestic ruminants is considered to be an effective strategy for protecting these animals against Rift Valley fever (RVF), but available vaccines have limitations. Therefore, the aim of this study was to determine the safety and immunogenicity of RVF virus (RVFV) mutagenesis passage 12 (MP-12) and arMP-12ΔNSm21/384 vaccine candidates in goats (Capra aegagrus hircus) in Tanzania. Goats were vaccinated intramuscularly with RVFV MP-12 or arMP-12ΔNSm21/384, and then on Day 87 post-vaccination (PV) all animals were revaccinated using the RVFV MP-12 vaccine candidate. Serum samples were collected from the animals before and after vaccination at various intervals to test for RVFV using a Vero cell culture assay and reverse transcription polymerase chain reaction and for RVFV-neutralising antibody using a plaque reduction neutralisation assay. Serum samples collected before vaccination on Days -14 and 0, and on Days 3, 4 and 5 PV were negative for RVFV and neutralising antibody. All animals remained healthy, and viremia was not detected in any of the animals. Rift Valley fever virus antibody was first detected on Day 5 PV at a 1:10 dilution in five of five animals vaccinated with the MP-12 vaccine and in five of eight animals vaccinated with arMP-12ΔNSm21/384. Titres then increased and were sustained at 1:40 to 1:640 through to Day 87 PV. All animals that were revaccinated on Day 87 PV with MP-12 developed antibody titres ranging from 1:160 to as high as 1:10 240 on Days 14 and 21 PV. Although the antibody titres for goats vaccinated with RVF MP-12 were slightly higher than titres elicited by the arMP-12ΔNSm21/384 vaccine, these findings demonstrated that both vaccines are promising candidates for the prevention of RVF among Tansanian goats. |
https://data.usaid.gov/d/2k6j-e69h |
|
21 |
In this study, livestock were vaccinated intradermally with 5 log10 pfu of MP-121-NSm-del Rift Valley fever live, attenuated vaccine using the Bioject Zetajet developmental device. Neutralizing antibody titers (expressed as a reciprocal) were determined by the 80% Plaque Reduction Neutralization technique (PRNT-80) at days post vaccination (DPV).
The overall purpose of the Feed the Future Innovation Lab for Rift Valley Fever Control in Agriculture is to increase the food supply by developing and applying a vaccine for the prevention of Rift Valley fever disease among livestock in Africa. Rift Valley Fever (RVF) is a mosquito-borne viral disease that continues to have a devastating impact on human and animal health in Africa. Since the discovery of RVF as the cause of an outbreak among sheep and humans during the early 1930s in the Rift Valley in Kenya, the disease has emerged as one of the most important zoonoses in Africa. The disease has and continues to affect the health of thousands to millions of humans and animals, and the livestock industry has lost millions of dollars, and therefore, affecting hundreds of millions of those whose livelihood depends on livestock, exaggerating poverty on already deprived communities.
The specific aim of the Lab is to conduct a 5 year research project to develop and evaluate a vaccine for the prevention of Rift Valley fever (RVF) among livestock in Tanzania and other RVF virus enzootic African regions and thereby improve food security, nutrition and livelihoods in Africa as a USAID priority under Feed the Future, the U.S. Government’s global hunger and food security initiative. This data asset reports the results of this work. |
https://data.usaid.gov/d/hxak-vmjt |
|
21 |
All animals were given 3 log-10 pfu of MP-12 vaccine intramuscularly at DPV 84 as a surrogate challenge for RVFV, and the anamnestic immune response determined by PRNT-80 titers thereafter on the days shown. This demonstrated that animals pre-vaccinated with either MP-122 or the deletion variant MP-121-NSm-del exhibited an enhanced response indicative of priming for the response by the initial vaccination. Access data in file Antibody_results_intramuscular.xlsx
The overall purpose of the Feed the Future Innovation Lab for Rift Valley Fever Control in Agriculture is to increase the food supply by developing and applying a vaccine for the prevention of Rift Valley fever disease among livestock in Africa. Rift Valley Fever (RVF) is a mosquito-borne viral disease that continues to have a devastating impact on human and animal health in Africa. Since the discovery of RVF as the cause of an outbreak among sheep and humans during the early 1930s in the Rift Valley in Kenya, the disease has emerged as one of the most important zoonoses in Africa. The disease has and continues to affect the health of thousands to millions of humans and animals, and the livestock industry has lost millions of dollars, and therefore, affecting hundreds of millions of those whose livelihood depends on livestock, exaggerating poverty on already deprived communities.
The specific aim of the Lab is to conduct a 5 year research project to develop and evaluate a vaccine for the prevention of Rift Valley fever (RVF) among livestock in Tanzania and other RVF virus enzootic African regions and thereby improve food security, nutrition and livelihoods in Africa as a USAID priority under Feed the Future, the U.S. Government’s global hunger and food security initiative. This data asset reports the results of this work. |
https://data.usaid.gov/d/peta-tny3 |
|
21 |
The objective of this study was to evaluate the safety and immunogenicity of a live, attenuated recombinant RVF arMP-12ΔNSm21/384 nucleotide deletion vaccine candidate in domestic ruminants. . The immunogenicity of 2 doses of 104 and 105 Tissue Culture Infectious Doses50% (TCID50) of the vaccine was assessed in of 2 groups of 10 sheep, 2 groups of 10 goats, and doses of 105 and 106 TCID50 were used to vaccinate 2 groups of 10 calves. The results showed that the immunogenicity among sheep, goats and cattle indicated that doses of 104 - 106 TCID50 elicited detectable antibody by day 7 post-vaccination and antibody titers that ranged from 1:14 to 1:305 on day 14 PV with sustained titers through day 28 PV. Overall, these findings indicated that the RVF arMP-12ΔNSm21/384 vaccine is a promising candidate for the prevention of RVF among domestic ruminants. |
https://data.usaid.gov/d/fc4b-6abn |